CBQA SCHEDULE

This schedule is subject to change without notice.
PLEASE CHECK BACK REGULARLY FOR UPDATES. THERE ARE NEW RUNS BEING DEVELOPED. FOR EXAMPLE, PD-L1 ASSAYS FOR BREAST CANCER, UROTHELIAL CANCER, AND OTHERS.
DATES MODULE/RUN Test Performance Characteristic(s) DRUG STATUS
2020 Feb PD-L1 (NSCLC) Reportable Range
Accuracy
Analytical Sensitivity
Pembrolizumab
Nivolumab
Atezolizumab
In progress
2020 Feb PD-L1 (Calibrators) Quantitative Analytical Sensitivity Calibration In progress
2020 Feb ROS1 (NSCLC) Accuracy Crizotinib In progress
2020 Jun PD-L1 (NSCLC) Accuracy Any drug/purpose Upcoming (APPLY)
2020 Jun PD-L1 (Calibrators) Quantitative Analytical Sensitivity Calibration Upcoming (APPLY)
2020 Jun ROS1 (NSCLC) Accuracy Crizotinib Upcoming (APPLY)
2020 Oct PD-L1 (NSCLC) Accuracy Any drug/purpose Upcoming (APPLY)
2020 Oct PD-L1 (Calibrators) Quantitative Analytical Sensitivity Calibration Upcoming (APPLY)
2020 Oct ROS1 (NSCLC) Accuracy Crizotinib Upcoming (APPLY)